JN.1
A New Threat to Global Health
DOI:
https://doi.org/10.33043/yrxbqqaaKeywords:
JN.1, coronavirus, variant, outbreak, global healthAbstract
JN.1 is a novel coronavirus variant that emerged in Luxembourg in August 2023 and has since spread to several countries. It is characterized by a high transmissibility, and is causing a global surge of infections, hospitalisations, ICU admissions and deaths, and may surpass the previous Omicron waves. Current vaccines, treatments and testing are expected to remain effective, but more studies are needed to confirm this. This short communication provides an overview of the epidemiological, clinical, and virological features of JN.1 and its impact on global health.
Downloads
References
Looi M. K. (2023). Covid-19: WHO adds JN.1 as new variant of interest. BMJ (Clinical research ed.), 383, 2975. https://doi.org/10.1136/bmj.p2975
Bai, C., Zhong, Q., & Gao, G. F. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Science China. Life sciences, 65(2), 280–294. https://doi.org/10.1007/s11427-021-1964-4
Kosugi, Y., Plianchaisuk, A., Putri, O., Uriu, K., Kaku, Y., Hinay, A. A., Jr., Chen, L., Kuramochi, J., Sadamasu, K., Yoshimura, K., Asakura, H., Nagashima, M., The Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito, J., & Sato, K. (2023). Virological characteristics of the SARS-CoV-2 Omicron HK.3 variant harboring the “FLip” substitution. bioRxiv. https://doi.org/10.1101/2023.11.14.566985
Tamura, T., Mizuma, K., Nasser, H., Deguchi, S., Padilla-Blanco, M., Oda, Y., Uriu, K., Tolentino, J. E. M., Tsujino, S., Suzuki, R., Kojima, I., Nao, N., Shimizu, R., Wang, L., Tsuda, M., Jonathan, M., Kosugi, Y., Guo, Z., Hinay, A. A., Jr, Putri, O., … Sato, K. (2024). Virological characteristics of the SARS-CoV-2 BA.2.86 variant. Cell host & microbe, 32(2), 170–180.e12. https://doi.org/10.1016/j.chom.2024.01.001
Liu, Z., Zhou, J., Wang, W., Zhang, G., Xing, L., Zhang, K., Wang, Y., Xu, W., Wang, Q., Man, Q., Wang, Q., Ying, T., Zhu, Y., Jiang, S., & Lu, L. (2024). Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD. Cell Reports Medicine, 5.
ASIT KUMAR CHAKRABORTY. Higher Omicron JN.1 Coronavirus Transmission due to Unique 17MPLF Spike Insertion compensating 24LPP, 69HV, 145Y, 211N and 483V deletions in the spike, 04 January 2024, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-3830998/v1]
Hang Fan, Si Qin and Yujun Cui. Emergence and Characterization of the SARS-CoV-2 JN.1 Variant: Global Prevalence and Implications for Public Health. Zoonoses. 2024. Vol. 4(1). DOI: 10.15212/ZOONOSES-2023-0061
Topol, E. (2024, January 4). Covid-2024: Flu Virus Vaccine. Los Angeles Times
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Neelabh Datta
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
By submitting to Fine Focus, the author(s) agree to the terms of the Author Agreement. Beginning in Fall 2018, all authors retain copyrights associated with their article contributions and agree to make such contributions available under a Creative Commons Attribution-NonCommercial 4.0 International license upon publication in Fine Focus. Copyrights to articles published prior to Fall 2018 have been transferred from the authors to Fine Focus.
